The Alzheimer's disease 2024 drug development pipeline An often heard critique is that the Alzheimer field is too “amyloid-centric”. The Figure below actually shows a well-diversified drug pipeline, which is highly needed. The mechanisms of action (CADRO) for agents currently being tested in phase 2 clinical trials (n=90) are: 1. Inflammation (23%) 2. Neurotransmitter receptors (19%) 3. Amyloid (12%) 4. Synaptic plasticity (12%) 5. Tau (7%) 6. Other [eg, Metabolism, Oxidative stress, Lipids] (27%) Link to Cummings et al. > alz-journals.onlinelibrary.w… #Alzheimers #Dementia #EndAlz #drugs #trials

So excited and honored to be invited to present the opening plenary at #AIC2025 this year in Toronto! 🧠 🙏 I would be very grateful if you could help me gather the most inspiring papers (including your own!) of the past year by completing this survey: alz.surveymonkey.com/r/923BT…

🚨NEW PREPRINT: An atypical phenotype is a risk factor for higher mortality in Alzheimer’s disease @ilse_bader shows that an atypical (non-amnestic-predominant) clinical presentation is an important risk factor for mortality beyond age, sex, education, APOEε4-carriership and disease severity. Link @medrxivpreprint: medrxiv.org/content/10.1101/… @Colin__Groot @AlzheimerAms

Survey among experts on the future role of tau-PET in clinical practice and trials Check out our latest work led by @vermeiren_marie & @IsmaelLCalandri, describing the results of a survey among 268 dementia experts on the future role of Tau PET in the clinic and trials. Many thanks to all respondents!!! Link (open access) > alz-journals.onlinelibrary.w… @AlzheimerAms

FYI.

IWG 2024 vs AA 2024 criteria for Alzheimer disease A comparison between the recently proposed Alzheimer Association criteria vs the updated IWG criteria for AD. Differences are in the Table below: mainly comprising differing views on AD as a "biological" vs "clinical-biological" entity and therefore most pronounced in cognitively unimpaired individuals. Link to paper > jamanetwork.com/journals/jam…

📢Job alert! Join the BioFINDER team as a Grant Manager👇🏽

Pleased to present the design paper of a Dutch multicenter study in which we aim to assess the clinical value of Tau PET, led by @vermeiren_marie (@AlzheimerAms). "The impact of tau-PET in a selected memory clinic cohort: rationale and design of the TAP- TAU study" Link to paper @AlzheimersRes: alzres.biomedcentral.com/art…

Pleased to present our recent publication @AlzheimersRes on "Biological mechanisms of resilience to tau pathology in Alzheimer’s disease", led by Anna Svenningson and Diana Bocancea. Link to paper: alzres.biomedcentral.com/art… w/@EStomrud, @NiklasMattsson4, @SebastianPalmqv, @OskarHansson9, @AlzheimerAms, @biofinder_study.

Pointing at the culprit.

REAL AD - Validation of a realistic screening approach for early Alzheimer's disease This large-scale study led by @_michael_scholl will learn us a lot about population-based screening with plasma biomarkers of Alzheimer's disease pathophysiology. Link to the design paper (open-access): alz-journals.onlinelibrary.w…

On the train back to Amsterdam after a wonderful first @eumind_congress, I think is here to stay! It was a pleasure to give a talk on “AT(N) imaging in atypical variants of Alzheimer’s disease”.

Association of in vivo retention of Flortaucipir PET with tau neuropathology in corresponding brain regions Check out our most recent publication, led by @to_freiburghaus & @DW_Pawlik at Acta Neuropathologica. Main findings: 1⃣ Flortaucipir PET signal primarily reflects tau pathology, also at relatively low densities of tau proteinopathy 2⃣ Flortaucipir PET does NOT bind substantially to tau neurites in neuritic plaques or in individuals with PART Link to paper (open access): link.springer.com/article/10… Link to @biofinder_study 🧵: x.com/biofinder_study/status… w/@AntoineLeuzy @jorittmo @cece_tremblay @ErikRubenSmith @OskarHansson9

isFTD2024 in Amsterdam has started! A great musical intro, official opening by local organizer Yolande Pijnenburg (@AlzheimerAms), a touching speech by Emma Heming Willis (FTD advocate and partner of Bruce Willis) and an opening plenary by Elisabet Englund (@lunduniversity) about the history of FTD.

I attended the FTD-ALS workshop (isFTD pre-conference in Amsterdam) this morning, learned a lot about TDP-43!

Lewy body pathology exacerbates brain hypo-metabolism and cognitive decline in Alzheimer’s disease Great work led by @LECollij. Using ADNI data, she showed that the presence of LB pathology (CSF SAA) exacerbates global cognitive decline in symptomatic AD and is associated with more pronounced hypo-metabolism (FDG PET), particularly in posterior cortical regions. Link @NatureComms (open access): nature.com/articles/s41467-0… @biofinder_study @SEMastenbroek @NiklasMattsson4 @SebastianPalmqv @OskarHansson9

Very proud of Anna Svenningson who defended her PhD thesis today very well. Also many thanks to opponent Prof. Geir Saelback for creating a great atmosphere leading to a high-level scientific discussion about resilience in Alzheimer’s disease. W/@OskarHansson9 @SebastianPalmqv @EStomrud @biofinder_study

Proteomic changes in Alzheimer disease associated with progressive Aβ plaque and tau tangle pathologies Very elegant work from @biofinder_study, led by @alexa_pichetb, @_JakeVogel_ & @OskarHansson9. Link at @NatureNeuro > nature.com/articles/s41593-0…

The BeyeOMARKER study design paper is out! In BeyeOMARKER we will screen 700 individuals with plasma p-tau217 at an eye clinic, and further characterize 150 of them with Amyloid & Tau PET, MRI, retinal imaging and cognitive & cortical vision assessment. Thanks to the great team at @AlzheimerAms, especially @ilse_bader, @j_milongo & @Colin__Groot. Link to paper @AlzheimersRes (open access) > pubmed.ncbi.nlm.nih.gov/3916…

Time for an update! @IsmaelLCalandri @Gill_Livingston @reparadela @LuCrivelliOk @NeuroAllegri @clausuemoto

The figure we all have to learn by heart: The updated Lancet Commission on potentially modifiable risk factors for dementia. #AAIC24